Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly twice-daily oral docetaxel with ritonavir dose-finding study
NL-OMON39193Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of docetaxel and ritonavir in cancer and Non-hematologic malignancy (4 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Maximum tolerated dose of ModraDoc001 plus ritonavir. Started Apr 2010; status: active, not recruiting.
02
Drugs
docetaxelritonavir
03
Conditions
cancerNon-hematologic malignancy
Beyond the preview
Go deeper on NL-OMON39193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39193.